Table 1.
Reasons for premature discontinuation of the trial
| Patient status | Placebo (n (%)) | ASU-E (n (%)) | Total (n (%)) |
|---|---|---|---|
| Randomised patients | 210 (100) | 189 (100) | 399 (100) |
| Completers | 127 (60.5) | 106 (56.1) | 233 (58.4) |
| Premature withdrawals | 83 (39.5) | 83 (43.9) | 166 (41.6) |
| Inefficacy with total joint replacement | 36 (17.1) | 38 (20.1) | 74 (18.5) |
| Inefficacy without total joint replacement | 9 (4.3) | 8 (4.2) | 17 (4.3) |
| Adverse events | 11 (5.2) | 10 (5.3) | 21 (5.3) |
| Consent withdrawal | 11 (5.2) | 17 (9.0) | 28 (7.0) |
| Lost to follow-up | 8 (3.8) | 3 (1.6) | 11 (2.8) |
| Other | 7 (3.3) | 6 (3.2) | 13 (3.3) |
| Deaths | 1 (0.5) | 1 (0.5) | 2 (0.5) |
ASU-E, avocado–soybean unsaponifiable—Expanscience.